Assessing The Effectiveness and safety of Nasal NeuroEpo management in patients with Alzheimer's mild/moderate - ATHENEA

Center of Molecular Immunology (CIM)0 sites174 target enrollmentFebruary 1, 2017

Overview

No summary available.

Registry

who.int

Start Date

February 1, 2017

End Date

September 14, 2021

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Center of Molecular Immunology (CIM)

•1\- Patients with ages \= to 50 years.
•2\- Patients with GDS between 2 to 4 points.
•3\- Patients with permeable airways.
•4\- Patients (or tutor, if the patient can not) grant consent to participate in the study by signing the informed consent model.
•5\- Patient with caregiver or legal tutor physically and mentally willing to collaborate with the investigation.

•1\- Negative patient or caregiver (if the patient is incapacitated) to participate in the study.
•2\- Evident mental disability or other limitation that prevents the patient or caregiver from signing their consent or hindering the study evaluations.
•3\- Patients with neurological symptoms or signs that suggest another cause of dementia.
•4\- Skull trauma or recent intracranial surgery.
•5\- Clotting disorders known.
•6\- Patients where coexistence of another disease or condition that may lead to significant disability (cancer, septic embolism, endocarditis, myeloproliferative disease, creatinine\> 3 mg / dl (265µmol / L), hyperkalemia\> 5\.0 mmol / L, chronic/severe liver or kidney or heart disorders.
•7\- Patients with a history of hypersensitivity to EPO\-hr.
•8\- Patients with known allergy to any ingredients of the product.
•9\- Patients who present nasal irritation (sneezing) or a runny nose before starting treatment.
•10\- Patients who present asthma attack at the begining of the treatment.